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Carcinogenic Risk Assessment:
Comparison of Estimated Safe Doses
for Rats and Mice
by James J. Chen* and David W. Gaylor*
Datafrom the National Cancer Institute/National Toxicology Program (NCI/NTP) carcinogenesis bioas-
says were examined to compare cancer risks in rats and mice. Only those bioassays where chemicals were
administered orally were used. The ratios for rats to mice ofthe virtually safe dose (VSD) levels associated
with a risk of 10-' were compared. Comparisons of the ratios were made for those chemicals that NCI/
NTP determined to be carcinogenic in at least one species and that showed a dose response trend in the
same sex at the same tissue/organ site in the other species. In all, 69 comparisons from 38 carcinogens
were performed. The overall geometric mean of the VSD ratios is 1.27 in terms of concentration (ppm);
the mean and the standard deviation in logarithm are 0.24 and 1.83, respectively. The VSD ratios vary
from 1:51 to 49:1. Without the restriction of the same sex and site, the geometric mean of the minimum
VSDs is 1.38, and the standard deviation in logarithm is 1.79. By directly comparing the VSDs for rats
and mice (as they are performed for risk assessment), this study showed a probability of 0.10 that the
ratio ofVSDs is greater than 10, and the ratio is greater than 20 with a probability of0.05 when a chemical
is carcinogenic in both species.
Introduction
From a scientific standpoint, it would be desirable
to measure the carcinogenic effects of chemicals in
human populations in order to obtain information for
regulatory decisions. Because of the lack of human
data for many chemicals, experiments in laboratory
animals must generally be used to quantify risk as a
function of dose. The question often arises as to the
relevancy ofthe results from animal experiments for
predicting cancer risks in humans. Several studies of
interspecies comparisons of carcinogenic potencies
have been conducted (1-5). Those studies, in general,
showed interspecies correlations between the carcin-
ogenic potencies in three rodent species: rats, mice,
and hamsters.
For regulatory decision purposes, we are most inter-
ested in the comparisons of doses between species at
the low response rates. Regulatory agencies are fre-
quently using risk assessment approaches to establish
safe levels of exposure of chemicals at a given level of
low risk, e.g., 10-6. The purpose of this paper is to
compare the virtually safe dose levels ofcarcinogens in
rats and mice from data obtained by the NCI/NTP
bioassays. These comparisons provide an indication of
the size of the uncertainty factor required to allow for
difference in cancer risks between rats and mice.
*FDA/Biometry, National Center for Toxicological Research, Jef-
ferson, AR 72079.
Method
The data collected by the NCI/NTP carcinogenesis
screening program is available to compare cancer
rates in rats and mice. Only bioassays in which chem-
icals were administered orally were considered in this
paper. Thesebioassaysgenerallyemployed50animals
each at the maximumtolerated dose (MTD), 1/2MTD,
and 0 dose controls in both sexes of rats and mice.
Osborne-Mendel, Sprague-Dawley, or Fischer 344
rats were used. B6C3F1 hybrid mice were used in all
cases.
From a risk assessment viewpoint, we are inter-
ested in quantifying the extra risk of exposure to a
chemical at a certain dose level. Let P(d) represent
the risk (probability) that an animal will develop a
tumor at dose d. The quantity P(d)-P(O) is the extra
risk of getting a tumor (over background) due to the
added dose d. The tumor rate at dose d is defined here
as the extra probability ofgetting a tumor given dose
d.
The tumor rates which are of concern in risk as-
sessment are usually at the 1% level or below. These
rates generally correspond to dose levels lower than
the experimental dose levels. Thus, estimates of the
1% level and below generally require extrapolation
from the experimental data and depend on the math-
ematical model chosen. The generalized multistage
dose response model ofCrump et al. (6) and the linear
extrapolation method for low dose assessment as pro-306 CHEN AND GAYLOR
posed by Gaylor and Kodell (7) were used here to
estimate a lower limit ofthe safe dose level for a risk
of 106. The estimated virtually safe dose (VSD) is
given by
VSD= de X10-6 U(de)
where u(de), obtained by fitting the Crump multistage
model, is the upper confidence limit at the lowest ex-
perimental dose de or the dose estimated to produce a
1% tumor incidence; whichever dose is larger.
TheratiosoftheVSDsinratstoVSDsinmiceprovide
ameasureoftherelativepotencyofcarcinogens. Crouch
and Wilson (8) proposed using a lognormal model for
theinterspecies sensitivityratio. Assumethattheratios
of VSDs are lognormally distributed and represent a
sample ofall chemicals in use. The mean and standard
deviation ofthe logarithms ofthe VSD ratios were com-
puted to compare with the results of Crouch (2) and
Gaylor and Chen (5), in which different measures for
the relative potency of carcinogens were used. The
mean and the standard deviation provide measures of
an average and variability for the overall agreement
between rats and mice. A study of the variations of
individual VSD ratios, which are related to the partic-
ular dose response model and the low dose assessment
procedure used in the computations, are beyond the
context ofthis paper.
The geometric mean, which is the antilogarithm of
the mean ofthe logarithms of the VSD ratios, is used
for comparing the overall agreement between the two
species. If the logarithms of the VSD ratios have a
normaldistribution withmeanlogu, thenthegeometric
meanisthemaximumlikelihood estimatorofthemedian
ofthe lognormal distribution, u.
Two hundred fifteen NCI/NTP chemical bioassays
were examined. Comparisons of the VSD ratios were
only made for those chemicals determined to be carcin-
ogenic by the NCI/NTP in at least one species and that
showed a dose response trend in the same sex at the
same tissue/organ site in the other species. Thus, our
investigation does not cover those cases where a chem-
ical is carcinogenic in only one species, or both species,
but not at the same site in the same sex. We assumed
imposing the restriction that the tumors must be in the
same tissue/organ site in the same sex would provide a
goodpredictabilitywhenachemicalwaspotentially car-
cinogenic in both species and when the same chemical
was tested with similar protocols in the different spe-
cies.
Results
The ratios of the VSDs are given in Table 1. In all,
69 comparisons were made for 38 chemicals. Thirty-
three comparisons are forfemales and 36 are formales.
Six comparisons are for Sprague-Dawley rats, 11 com-
parisons are for Osborne-Mendel rats, and 52 compar-
isons are for Fischer 344 rats. Thirty-one comparisons
are for liver tumors, and the remaining 38 are at a
variety oftissue sites. Asummaryoftheresultsbysex,
by rat strain, and by liver versus nonliver tissue site is
given in Table 2.
The overall geometric mean ofthe VSD ratios is 1.27
in terms ofconcentration (ppm); this means that on the
average, the VSD for the rat is 1.27 times higher than
the VSD forthe mouse. The VSD ratios vary from 1:51
to 49:1. The standard deviation ofthe logarithm ofthe
ratio is about 1.83. The correlation between the loga-
rithms ofVSDs for rats and mice is 0.69, which is sta-
tistically significant.
The geometric mean ratio is higherforfemales (1.39)
than for males (1.17). The standard deviation is higher
for females (1.91) than for males (1.78). In 46 out of69
comparisons, data in the same tissue/organ site were
available for both males and females. Comparing the
VSD ratios between males and females can provide an
indication of the interaction effect of sex and species.
The agreementbetweenmales and femalesisgood; that
is, the species difference between rats and mice is con-
sistent whether males or females are evaluated. For 2
of 23 comparisons, or 9%, the ratios of the VSD ratio
inmalestothe VSD ratioinfemales differbymorethan
a factor of 10. The chemicals in which this pattern was
observed are phenoxybenzamine HCl (1:14.1), and
HCDD (1:13.3).
The geometric means for Sprague-Dawley, Osborne-
Mendel, and Fischer 344 rat strains are 1.78, 1.68, and
1.15, respectively. The geometric mean for rats to mice
is higher for liver tumor (3.03) than for tumors at the
other sites (0.63).
The agreement ofVSDs between rats and mice was
good, on the average. However, for individual com-
pounds the agreement was not always good, even
though carcinogenicitywas observed inthe same sex at
the same tissue/organ site for rats and mice. For 16 of
the69comparisons (23%), theVSDratiosdifferbymore
than a factor of 10. A stem-and-leafplot (9) ofthe VSD
ratios is shown in Figure 1. The largest discrepancies
(factors of 1/50, 1/35, 1/27, 1/22) for which the rats ap-
pear more sensitive than the mice are produced by the
three compounds: o-Anisidine HCI, Tris, and Cupfer-
ron. The largest discrepancies (factors of49, 37, 30) for
which the mice appear more sensitive than the rats all
occur in females and are produced by amino ethylcar-
bazole HCI, 2,4,5-trimethylailine, and 1,1,1,2-tetrachlo-
roethane.
The ratios ofVSDs differed by a factor of1.27 onthe
average; without a restriction to the same sex and site,
agreement ofVSDs between rats and mice was similar.
The minimum VSDs from the mixtures of sites and
sexes in each species were computed for the 38 chem-
icals. The geometric mean ofthe ratios ofthe miniimum
VSDs was 1.37 and the standard deviation inlogarithm
was 1.79. The ratios of the VSDs varied from 1:47 to
26:1.
Discussion
The VSD levels were computed for a risk level of
10 6bythelinearextrapolationmethod. Atthelowrisk
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Table 1. Estimates of the ratios of VSDs in rats and mice.
Chemical Site Rate straina Sex VSD ratio, rats:mice
Thio-tepa Skin SD M 1.4
Thio-tepa Lymph SD M 1.9
Thio-tepa Lymph SD F 15.1
Phenesterin Hematopoetic SD M 3.8
Phenoxybenzamine HCl Peritoneum SD M 1/8.3
Phenoxybenzamine HC1 Peritoneum SD F 1.7
1,2-Dibromoethane Forestomach OM M 1/2.4
1,2-Dibromoethane Forestomach OM F 1/2.0
1,2-Dichloroethane Subcutaneous OM M 1/1.9
1,2-Dichloroethane Mammary OM F 3.1
1,4-Dioxane Liver OM F 2.1
Sulfallate Mammary OM F 1/1.1
HCDD Liver OM M 14.8
HCDD Liver OM F 1.1
TCDD Liver OM M 16.1
TCDD Liver OM F 2.1
TCDD Thyroid OM F 1/1.1
NTA Kidney F344 M 6.7
Thiodianiline Thyroid F344 M 1/4.5
Thiodianiline Thyroid F344 F 1/12.7
TRIS Kidney F344 M 1/35.1
Diaminoanisole S04 Thyroid F344 M 1/2.8
Diaminoanisole S04 Thyroid F344 F 1/2.5
o-Anisidine HCI Bladder F344 M 1/50.3
o-Anisidine HCl Bladder F344 F 1/26.8
Hydrazobenzene Liver F344 F 3.4
Amino ethylcarbazole HCl Liver F344 M 9.4
Amino ethylcarbazole HCI Liver F344 F 48.9
(Chloromethyl) pyridine HCI Bladder F344 M 6.6
Amino ethoxyacetanilide Thyroid F344 M 1.3
Amino ethoxyacetanilide Thyroid F344 F 1/1.1
Dimethoxybenzidine diisocyanate Hematopoietic F344 M 1/3.7
Dimethoxybenzidine diixocyanate Hematopoietic F344 F 1/1.6
1,5-Naphthalenediamine Thyroid F344 M 2.5
1,5-Naphthalenediamine Thyroid F344 F 1.6
1,5-Naphthalenediamine Lung F344 M 1.4
2-Aminoanthraquinone Liver F344 M 2.2
2,4,5-Trimethylaniline Liver F344 M 15.2
2,4,5-Trimethylaniline Liver F344 F 37.4
2,4,5-Trimethylaniline Lung F344 F 5.0
Michler's ketone Liver F344 F 1/8.1
p-Chloroaniline Spleen F344 M 1/2.3
Fluometuron Liver F344 M 1.1
Cinnamyl anthranilate Liver F344 M 9.5
4,4'-Oxydianiline Liver F344 M 1/2.1
4,4'-Oxydianiline Liver F344 F 2.6
4,4'-Oxydianiline Thyroid F344 M 1/8.0
4,4'-Oxydianiline Thyroid F344 F 1/12.7
Di(ethylhexyl) phthalate Liver F344 M 7.7
Di(ethylhexyl) phthalate Liver F344 F 4.8
Dichloro-p-phenylenediamine Liver F344 M 2.9
Dichloro-p-phenylenediamine Liver F344 F 4.3
C.I. Disperse Yellow 3 Liver F344 F 12.4
D&C Red No. 9 Liver F344 M 1.5
C.I. Solvent Yellow 14 Liver F344 M 1/4.9
C.I. Solvent Yellow 14 Liver F344 F 1/2.3
1,1,1,2-Tetrachloroethane Liver F344 M 7.4
1,1,1,2-Tetrachloroethane Liver F344 F 30.0
Dimethylenedianiline DiHCl Thyroid F344 M 1/1.0
Dimethylenedianiline DiHCl Thyroid F344 F 1/2.4
Dimethylenedianiline DiHCI Liver F344 M 1.4
Dimethylenedianiline DiHCI Liver F344 F 3.2
p-Nitrosodiphenylamine Liver F344 M 1/1.4
Cupferron Heart F344 M 1/14.5
Cupferron Heart F344 F 1/11.8
Cupferron Liver F344 F 1/22.1
p-Cresidine Bladder F344 M 7.64
p-Cresidine Bladder F344 F 2.22
2,4-Diaminotoluene Liver F344 F 9.65
aSD = Sprague-Dawley; OM = Osborne-Mendel; F344 = Fischer 344.
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Table 2. Summary ofthe ratios of VSD in rats to VSD in mice.
Number of Ratios
Comparison groups comparisons Geometric mean Log mean Log SD Minimum Maximum
Males 36 1.17 0.16 1.78 1:50.3 16.1:1
Females 33 1.39 0.33 1.91 1:26.8 48.9:1
Sprague-Dawley 6 1.78 0.58 1.58 1:8.3 15.1:1
Osborne-Mendel 11 1.68 0.52 1.27 1:2.4 16.1:1
Fischer 344 52 1.15 0.14 1.96 1:50.3 48.9:1
Liver 31 3.03 1.11 1.67 1:22.1 48.9:1
Nonliver 38 0.63 -0.46 1.66 1:50.3 15.1:1








































Figure 1. Stem-and leaf plot ofthe VSD ratios.
levels (1% or below), the VSD was approximately pro-
portional to the corresponding risk level. For example,
the VSD forthe risk of i0-5 was approximately a factor
of 10 higher than the VSD for a risk of 10-6. Thus, the
ratio of the VSD for rats to mice generally was not
affected by the choice of the level of risk.
Ninety-three of215 chemicals were found to have no
carcinogenic response in either species. These results
indicated that the two species were compatible in their
response to the chemicals. Thirty-eight chemicals in
which acarcinogenic response was found inboth species
at the same site in the same sex were compared in this
investigation. Our study does not cover the remaining
84 chemicals, 39 of which were negative in rats and
positive in mice, 26 of which were positive in rats and
negative in mice; and 19 ofwhich were positive in both
species but not at the same site. When a chemical is
positive in one species and negative in the other, it
cannot usually be decided on the basis of bioassay re-
sults alone as to whether such results represent true
discrepancies between the two species.
The disagreement ofVSDs between rats and mice in
the extreme cases mightberelatedtothe choice ofdose
response functions. For example, in the case of o-an-
isidine HCI, the observed responses forurinarybladder
tumors in the male rat were 0/51, 50/54, and 51/52 for
the control, low dose, and high dose, respectively. The
dose-response curve is not well defined in this instance
and may lead to imprecise VSD estimates. Specifically,
if the dose-response curve is sublinear below the ex-
perimental doseregion, thentheVSD willoverestimate
therisk. Ifthedose-response curveissupralinearbelow
the experimental dose region, the VSD will underes-
timate the risk. The multistage model has been used by
the EPA and FDA for cancer risk assessment with dif-
ferent approaches forlow-dose extrapolation. Whenthe
predicted excess risk at the lowest experimental dose
level is 1% or greater, the VSD estimates calculated
either by the linear extrapolation procedure of Gaylor
and Kodell (7) or by the linearized multistage model of
Crump et al. (6) differ little. For o-anisidine HCI, the
two extrapolation procedures have the same VSD es-
timate, 0.0016.
Zeise et al. (10) noted a correlation between carcin-
ogenic potency and the LD50 (dose that produces 50%
mortality). Bernstein et al. (4) suggested that the cor-
relation between the maximum tolerated dose (MTD)
and doses producing tumors may be fortuitous because
chronicbioassays aregenerally conducted inarelatively
narrowdoserangebelowtheMTD. Sincethe same dose
levels were often used for rats and mice for any given
chemical, differences in the VSDs for rats and mice are
somewhat restrained. When tumors are increased by a
chemical, these increases will tend to occur at nearly
the same dose levels, resulting in similar VSDs.
A purpose ofcarcinogenesis bioassays is to assist ex-
trapolation from animal to human risks. The VSD is
chosen here for the comparison between rats and mice,
as it has been used in risk assessment for predicting
human cancers. Crouch (2) compared the estimated
slope ofthe one-hit model between rats and mice for 66
compounds fromthe NCI/NTP bioassays. Additionally,
Peto et al. (11) proposed using the TD50 as a measure
for the carcinogenic potency; Gaylor and Chen (5) com-
pared the minimum TD50 for 190 compounds adminis-
tered in the diet from the database compiled by Gold
et al. (3). The mean and the standard deviation of the
logarithm (to base e) reported by Crouch (2) were 0.39
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and 1.52, respectively; the mean and the standard de-
viation reported by Gaylor and Chen (5) were 0.24 and
1.90, respectively. Inthis study, the meanand standard
deviation were 0.24 and 1.83, respectively. The com-
parisons of VSD ratios from the three different mea-
surements are in fair agreement. Moreover, the re-
striction to the same tissue/organ does not appear to be
much different from other investigations. In our study,
the means and the standard deviations are essentially
the same with or without the restriction.
The VSD ratio is assumed to have a lognormal dis-
tribution because it has a positive skew; that is, the
values of VSD ratios are spread over a wide range (0
to 49), but most values are between 0 and 10. An analy-
sis indicated that the lognormal model seemed appro-
priate for the distribution of VSD ratios. Assume that
the logarithms ofVSD ratios have anormaldistribution
with standard deviation s. Iffdenotes the factorforthe
interspecies extrapolation, thentheprobabilitythatthe
VSD ratio ofatypical chemicalwillfallwithinthefactor
fis P = 4+(a) - 4(-a), where a = (logJ)/s and + is the
standard normaldistributionfunction. Inthisstudy, the
estimated value of s is 1.83; thus, iff = 10, a factor of
10, then P = 0.79. This value is consistent with the
result shown in Figure 1, where about 77% ofthe VSDs
differ by less than a factor of 10.
Finally, we must consider the extrapolation from ro-
dents to humans. Assume that the variability of the
sensitive ratios of rats and mice shown in this study
couldrepresent the true variations betweentherodents
and humans. If the result of a rodent bioassay of a
chemical showed a positive carcinogenic effect with es-
timated VSD, v, then the probability of the VSD for
humans wasgreaterthanv/fwasP = +(a)(P was about
0.90 forf = 10 and P was 0.95 forf = 20), provided
that the chemical was carcinogenic for humans; but the
approach would be conservative when the chemical was
not carcinogenic for humans. In either case, there was
ajustification for quantitative estimates ofhuman can-
cer risk from animal studies. However, ifthe chemical
wasnotcarcinogenicforrodents, butitwascarcinogenic
forhumans, no estimate ofthe VSD would be made and
a cancer risk in humans would result.
The authors wish to thank the referees formanyhelpfulcomments.
REFERENCES
1. Crouch, E., and Wilson, R. Interspecies comparison of carcino-
genic potency. J. Toxicol. Environ. Health 5: 1095-1118 (1979).
2. Crouch, E. A. C. Uncertainties in interspecies extrapolations of
carcinogenicity. Environ. Health Perspect. 50: 321-327 (1983).
3. Gold, L. S., Sawyer, C. B., McGaw, R., Buckman, G. M.,
DeVecidna, M., Levinson, R., Hooper, N. K., Hevendor, W. R.,
Bernstein, L., Peto, R., Pike, M. C., and Ames, B. N. A carcin-
ogenic potency database of the standardized results of animal
bioassays. Environ. Health Perspect. 58: 9-319 (1984).
4. Bernstein, L., Gold, L. S., Ames, B. N., Pike, M. C., and Hoel,
D. G. Some tautologous aspects ofthecomparison ofcarcinogenic
potency in rats and mice. Fundam. Appl. Toxicol. 5: 79-87 (1985).
5. Gaylor, D. W., and Chen, J. Relative potency of chemical car-
cinogens in rodents. Risk Analysis 6: 283-290 (1986).
6. Crump, K. S., Guess, H. A., and Deal, K. L. Confidence intervals
and test of hypotheses concerning dose response relations in-
ferred from animal carcinogenicity data. Biometrics 33: 437-451
(1977).
7. Gaylor, D. W., and Kodell, R. L. Linear extrapolation algorithm
for low dose risk assessment of toxic substances. J. Environ.
Pathol. Toxicol. 4: 305-312 (1980).
8. Crouch, E., and Wilson, R. Regulation of carcinogens. Risk
Analysis 1: 47-57 (1981).
9. Tukey, J. W. Exploratory Data Analysis. Addison-Wesley Inc.,
New York, 1977.
10. Zeise, L., Wilson, R., and Crouch, E. Use of acute toxicity to
estimate carcinogenic risk. Risk Analysis 4: 187-199 (1984).
11. Peto, R., Pike, M. C., Bernstein, L. S., Gold, L. S., and Ames,
B. N. The TD50: aproposed general convention forthenumerical
description of the carcinogenic potency of chemicals in chronic-
exposure animal experiments. Environ. Health Perspect. 58: 1-
8 (1984).